GSK and Amicus Therapeutics Revise Migalastat Agreement

November 26, 2013
BioPharm International Editors

GSK and Amicus Therapeutics revise Fabry agreement entered into in July 2012.

GlaxoSmithKline (GSK) and Amicus Therapeutics have revised their drug-development under which Amicus has obtained global rights to develop and commercialize the investigational pharmacological chaperone migalastat HCl as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Under the terms of the revised agreement:

  • Amicus will have sole rights to the global drug development, regulatory and commercial activities for the next-generation Fabry ERT (migalastat HCl co-formulated with ERT) as well as migalastat HCl monotherapy

  • GSK will be eligible for future regulatory and commercial milestone payments, as well as royalty payments.

  • GSK will further invest $3 million in Amicus through an equity investment in a concurrent private placement in public equity (PIPE) transaction

Source: GlaxoSmithKline

Related Content:

Industry News | News